Smoldering Amiodarone‐Induced Decompensated Cirrhosis: Cumulative Dose–Related Toxicity
Case Reports in Gastrointestinal Medicine · 2026-01 · 2026 (1)
DOI: 10.1155/crgm/9933788 ↗Kurz gefasst
Fachartikel in der Zeitschrift Case Reports in Gastrointestinal Medicine, online erschienen am 24.05.2026. Verfasst von Jason Ta und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Tasmania, Hobart, Tasmania, Australia, utas.edu.au. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Tasmania.
Abstract (Originalsprache)
Amiodarone is a widely prescribed antiarrhythmic drug, but it can rarely cause severe progressive hepatotoxicity. This report presents a 74‐year‐old man on long‐term amiodarone therapy who developed tense ascites and cholestatic liver dysfunction after 12 years of continuous treatment, corresponding to a cumulative dose of 876 g. Five months prior to presentation, routine liver tests showed subtle and nonspecific abnormalities in liver enzymes, and there were no clinical stigmata of chronic liver disease. Quad‐phase CT imaging demonstrated features of chronic liver disease, with increased hepatic attenuation on the noncontrast phase, consistent with iodine deposition in the context of long‐term amiodarone exposure. Liver biopsy confirmed cirrhosis with ballooning hepatocytes, Mallory–Denk bodies, and neutrophilic satellitosis in the absence of steatosis, histological features suggestive of amiodarone‐induced liver injury. Secondary causes were excluded. Despite discontinuation of amiodarone and initiation of supportive therapy, the patient experienced recurrent decompensation. This case underscores the potential for subclinical progression of amiodarone‐induced liver injury, even in the presence of subtle or nonspecific abnormalities in liver biochemistry without a clear pattern to predict advanced fibrosis or imminent decompensation. Increased hepatic density on noncontrast CT imaging may serve as a radiologic indicator of drug deposition. Long‐term vigilance and monitoring of cumulative dose are essential for early detection and prevention of irreversible liver injury.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, University of Tasmania, Hobart, Tasmania, Australia, utas.edu.au.
- Department of Gastroenterology, Royal Hobart Hospital, Hobart, Tasmania, Australia, dhhs.tas.gov.au.
- Department of Anatomical Pathology, Royal Hobart Hospital, Hobart, Tasmania, Australia, dhhs.tas.gov.au.
ORCID-Profile: Jason Ta, Ritesh Bhandari, Junaid Beig
Förderung
- University of Tasmania
Zitieren
APA
Ta, J., Bhandari, R., Di Francesco, J., Roberts, A., Long, E., Chhabra, P., & Beig, J. (2026). Smoldering Amiodarone‐Induced Decompensated Cirrhosis: Cumulative Dose–Related Toxicity. Case Reports in Gastrointestinal Medicine, 2026(1). https://doi.org/10.1155/crgm/9933788
Vancouver
Ta J, Bhandari R, Di Francesco J, Roberts A, Long E, Chhabra P, et al. Smoldering Amiodarone‐Induced Decompensated Cirrhosis: Cumulative Dose–Related Toxicity. Case Reports in Gastrointestinal Medicine. 2026;2026(1). doi:10.1155/crgm/9933788
BibTeX
@article{Ta2026,
author = {Ta, Jason and Bhandari, Ritesh and Di Francesco, Joseph and Roberts, Austin and Long, Eileen and Chhabra, Puneet and Beig, Junaid},
title = {Smoldering Amiodarone‐Induced Decompensated Cirrhosis: Cumulative Dose–Related Toxicity},
journal = {Case Reports in Gastrointestinal Medicine},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crgm/9933788}
}
EUVIMED